IgG1 Monoclonal Antibody Ramucirumab Cas 947687-13-0
IgG1 Monoclonal Antibody Ramucirumab Cas 947687-13-0
| Product name:Ramucirumab | Purity:95% min |
| CAS NO:947687-13-0 | Solubility:Soluble in DMSO |
| Molecular Formula:C6374H9864N1692O1996S46 | Package:Package according to customer requirements |
| Molecular Weight:143.6 kg/mol | Storage:Store at -20℃ |
Ramucirumab is a fully human monoclonal antibody (IgG1). Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.
Related Prodcuts:
Pembrolimumab; Secukinumab; Infliximab; Ipilimumab; Atezolizumab; Daratumumab; Dulaglutide; Rituximab; Adalimumab; Bevacizumab; Aflibercept; Cetuximab
[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.
[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.